felbamate	phenytoin	3	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	none	none	none
felbamate	phenytoin	3	2	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	none	none	none
felbamate	phenytoin	3	4	true	positive	The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	none	none	none
felbamate	phenytoin	3	5	true	positive	The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	none	none	none
felbamate	phenytoin	4	2	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	none	none	none
felbamate	phenytoin	4	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	none	none	none
felbamate	phenytoin	4	5	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	none	none	none
felbamate	phenytoin	4	6	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	none	none	none
felbamate	phenytoin	5	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	none	none	none
felbamate	phenytoin	5	5	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	none	none	none
felbamate	phenytoin	5	6	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	none	none	none
felbamate	Felbatol	3	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	0	none	224900
felbamate	Felbatol	3	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	0	none	224900
felbamate	Felbatol	4	6	false	none	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	0	none	224900
felbamate	Felbatol	4	6	false	none	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	0	none	224900
felbamate	Felbatol	5	6	false	none	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	0	none	224900
felbamate	Felbatol	5	6	false	none	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	0	none	224900
felbamate	Phenytoin	3	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	8183	none	D010672
felbamate	Phenytoin	3	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	8183	none	D010672
felbamate	Phenytoin	3	2	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	8183	none	D010672
felbamate	Phenytoin	3	2	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	8183	none	D010672
felbamate	Phenytoin	3	4	true	positive	The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
felbamate	Phenytoin	3	4	true	positive	The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
felbamate	Phenytoin	3	5	true	positive	The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
felbamate	Phenytoin	3	5	true	positive	The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
felbamate	Phenytoin	4	2	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
felbamate	Phenytoin	4	2	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
felbamate	Phenytoin	4	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
felbamate	Phenytoin	4	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
felbamate	Phenytoin	4	5	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
felbamate	Phenytoin	4	5	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
felbamate	Phenytoin	4	6	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
felbamate	Phenytoin	4	6	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
felbamate	Phenytoin	5	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
felbamate	Phenytoin	5	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
felbamate	Phenytoin	5	5	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
felbamate	Phenytoin	5	5	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
felbamate	Phenytoin	5	6	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
felbamate	Phenytoin	5	6	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
phenytoin	Felbatol	1	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  		none	0	none	224900
phenytoin	Felbatol	1	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  		none	0	none	224900
phenytoin	Felbatol	2	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  		none	0	none	224900
phenytoin	Felbatol	2	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  		none	0	none	224900
phenytoin	Felbatol	4	6	false	none	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	0	none	224900
phenytoin	Felbatol	4	6	false	none	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	0	none	224900
phenytoin	Felbatol	5	6	false	none	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	0	none	224900
phenytoin	Felbatol	5	6	false	none	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	0	none	224900
phenytoin	Felbatol	6	6	false	none	In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	0	none	224900
phenytoin	Felbatol	6	6	false	none	In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	0	none	224900
phenytoin	Phenytoin	1	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  		none	8183	none	D010672
phenytoin	Phenytoin	1	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  		none	8183	none	D010672
phenytoin	Phenytoin	1	2	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	1	2	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	2	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	2	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	2	2	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	2	2	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	2	4	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	2	4	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	4	2	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	4	2	true	positive	In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  The steady-state Cmin increased to 21±5 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	4	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	4	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  		none	8183	none	D010672
phenytoin	Phenytoin	4	5	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
phenytoin	Phenytoin	4	5	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
phenytoin	Phenytoin	4	6	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
phenytoin	Phenytoin	4	6	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
phenytoin	Phenytoin	5	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
phenytoin	Phenytoin	5	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
phenytoin	Phenytoin	5	5	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
phenytoin	Phenytoin	5	5	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  		none	8183	none	D010672
phenytoin	Phenytoin	5	6	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
phenytoin	Phenytoin	5	6	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
phenytoin	Phenytoin	6	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
phenytoin	Phenytoin	6	4	true	positive	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
phenytoin	Phenytoin	6	5	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
phenytoin	Phenytoin	6	5	true	positive	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
phenytoin	Phenytoin	6	6	true	positive	In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
phenytoin	Phenytoin	6	6	true	positive	In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		none	8183	none	D010672
Felbatol	Phenytoin	1	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  		0	8183	224900	D010672
Felbatol	Phenytoin	1	1	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  		0	8183	224900	D010672
Felbatol	Phenytoin	1	2	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  		0	8183	224900	D010672
Felbatol	Phenytoin	1	2	true	positive	Phenytoin: Felbatol® causes an increase in steady-state phenytoin plasma concentrations.  In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 17±5 micrograms/mL.  		0	8183	224900	D010672
Felbatol	Phenytoin	6	4	false	none	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		0	8183	224900	D010672
Felbatol	Phenytoin	6	4	false	none	Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25±7 micrograms/mL.  In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		0	8183	224900	D010672
Felbatol	Phenytoin	6	5	false	none	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		0	8183	224900	D010672
Felbatol	Phenytoin	6	5	false	none	In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.  In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		0	8183	224900	D010672
Felbatol	Phenytoin	6	6	false	none	In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		0	8183	224900	D010672
Felbatol	Phenytoin	6	6	false	none	In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol® therapy resulted in phenytoin levels comparable to those prior to Felbatol® administration.  		0	8183	224900	D010672
